3852
I. T. Raheem et al. / Tetrahedron Letters 52 (2011) 3849–3852
2. Carroll, W. A.; Donnelley-Roberts, D.; Jarvis, M. F. Purinergic Signalling 2009, 5,
63–73.
3. U.S. Patent US005405848A; filed April 11, 1995.
4. Sanfilippo, P. J.; Urbanski, M.; Williams, L.; Press, J. B.; Katz, L. B.; Shriver, D. A.;
Fernandex, J. A.; Shatynski, D.; Offord, S. J. Eur. J. Med. Chem. 1992, 27, 655–661.
5. U.S. Patent Application WO2010138430; filed December 2, 2010.
6. Herrera, A.; Martinez-Alvarez, R.; Chioua, R.; Almy, J. Tetrahedron Lett. 2006, 47,
5463–5465.
identified a protocol that is both operationally simple and tolerates a
wide array of functional groups. In the context of our own drug
discovery program, this reaction has not only streamlined our lead
optimization process, but has also significantly impacted our
scale-up efforts as the transformation has been repeatedly executed
on >25-gram scale with excellent results. Current efforts are aimed
at expanding the substrate scope at both the amine and alkoxy
positions, as well as better understanding the pKa dependence of
the reaction. Our results will be disclosed in due course.
7. Representative experimental procedure: tert-butyl-2-phenyl-4-(prop-2-en-1-
yloxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate (4x).
A 10 mL
round bottom flask was charged with phenylamidinium hydrochloride
(31.7 mg, 0.203 mmol), 3-carbethoxy-4-piperidone hydrochloride (50 mg,
0.184 mmol), powdered K2CO3 (63.7 mg, 0.461 mmol), and a stirbar. The flask
was sealed and charged with DMF (1.23 mL) followed by allyl chloride (37.9 lL,
Acknowledgments
0.461 mmol). With vigorous stirring, the reaction mixture was heated to 70 °C
for 2 h, and reaction progress was monitored by LCMS. Upon completion of the
reaction, the reaction mixture was diluted with EtOAc (10 mL), and washed with
sat. aq NaHCO3 (10 mL) and brine (10 mL). The combined aqueous phases were
back-extracted with EtOAc (5 mL), and the combined organic phases were dried
over Na2SO4, filtered, and concentrated in vacuo. The resulting residue was
purified by gradient elution on silica gel (0–25% EtOAc/hexanes) to afford the
title compound as a colorless oil that slowly solidified upon standing (52.3 mg,
77%). 1H NMR (500 MHz, CDCl3): d 8.36–8.44 (m, 2H), 7.40–7.48 (m, 3H), 6.05–
6.17 (m, 1H), 5.44 (d, J = 17.3 Hz, 1H), 5.29 (d, J = 10.5 Hz, 1H), 5.05 (b s, 2H), 4.50
(b s, 2H), 3.75 (t, J = 5.5 Hz, 2H), 2.94 (b s, 2H), 1.51 (s, 9H) ppm; 13C NMR
(125 MHz, CDCl3): d 165.34, 161.65, 154.81, 137.64, 132.76, 130.39, 130.37,
128.38, 128.01, 118.03, 80.26, 66.89, 41.38, 40.50, 31.66, 28.46; HRMS (ES)
calculated M+H for C20H21N7O2S: 368.1963l; found:368.1969.
The authors thank the Merck West Point NMR and Mass Spec-
trometry facilities for assistance in characterizing the compounds
presented in this manuscript. Dr. Chris Cox and Mr. Thomas Steele
are also gratefully acknowledged for useful interactions.
References and notes
1. For representative reviews of MCCs see: (a) Armstrong, R. W.; Combs, A. P.;
Tempest, P. A.; Brown, S. D.; Keating, T. A. Acc. Chem. Res. 1996, 29, 123–131; (b)
Uqi, I. Pure Appl. Chem. 2001, 73, 187–191; (c) Dömling, A.; Ugi, I. Angew. Chem.,
Int. Ed. 2000, 39, 3168; (d) Dömling, A. In Multicomponent Reactions; Zhu, J.,
Bienayme, H., Eds.; Wiley-VCH: Weinheim, 2005; p 76; (e) Biggs–Houck, J. E.;
Ashkaan, Y.; Shaw, J. T. Curr. Opin. Chem. Biol. 2010, 14, 371–382.